However, the currently approved checkpoint inhibitors including anti-PD1/PD-L1 and anti-CTLA4 are only efficacious for CRC with a high level of microsatellite instability (MSI-H), which are only accounted for less than 10 % CRC cases. This evidence concerns the gene CTLA4 and colorectal carcinoma.